This article was originally published in The Gray Sheet
Executive SummaryEnrollment is under way for two separate, six-center, 25-patient, placebo-controlled U.S. trials of the HIF-1alpha angiogenesis product for use as an adjunct to CABG surgery, and for peripheral vascular disease, respectively. "The Gray Sheet" (Feb. 19, 2001, p. 18) incorrectly reported the studies were being conducted in Europe. In addition, the firm intends to start clinical trials for its second generation Carticel product in Europe sometime this year. The current version delivers harvested cartilage cells through open-knee surgery and not arthroscopically. Planned improvements will not include elimination of the cell harvesting procedure
You may also be interested in...
Financial ties between companies and healthcare bodies distort the production and use of evidence, claims a paper co-authored by researchers, clinicians and decision makers, including a representative of Germany’s HTA body, IQWiG.
Turku, Finland-based Forendo Pharma has entered into a license and collaboration deal with Novartis involving the identification of novel drugs to treat chronic liver diseases.
Three accelerated assessment requests will either be granted or rejected this week at the European Medicines Agency.